The current status of the use of vasodilator drugs in the treatment of acute and chronic heart failure has been reviewed. It is apparent that vasodilator treatment can be used effectively in some patients with heartfailure with a beneficial haemodynamic response, and that vasodilator agents are likely to find an important place in the management of such patients. Vasodilator treatment may be associated with complications and must be used with care. Though several nonparenteral vasodilator agents have been investigated, no ideal drug is yet available for the treatment of chronic heart failure. Nevertheless, it is probable that suitable drugs will emerge and find an important place in the management of such patients.
It has been shown that vasodilator therapy can improve cardiac performance in patients with heart failure, both acute and chronic. The ability of vasodilator drugs to increase cardiac performance is not related to a direct effect on the heart, since most of these agents have been shown to have no direct positive inotropic effects on the myocardium (Chatterjee et al., 1973a) . The two primary effects of these agents appear to be on the postcapillary capacitance bed and on the precapillary resistance bed. Vasodilator agents increase the venous capacitance, causing an increase in the relative size of the venous blood pool, a decrease in intracardiac blood volume (preload), and a decrease in systemic and pulmonary venous pressures. The other major effect of these drugs is to decrease arteriolar resistance and thus unload the heart; this unloading of the heart seems to be the most important mechanism whereby these drugs improve cardiac performance. It has been established in the isolated heart muscle preparation that with constant initial muscle length (preload), the degree of shortening is inversely proportional to afterload (Sonnenblick, 1962) . This suggests that inthe intact heart reduction in the afterload would result in enhanced myocardial fibre shortening and stroke ' This work was supported in part by a Program Project Grant from the U.S. Public Health Service. Received for publication 19 July 1976 volume. In relation to isolated muscle mechanics, the term afterload has been used to refer to the additional load above the preload, against which the muscle works as it shortens. To relate this concept to the intact heart, it is strictly necessary to measure wall stress during ejection, which according to the Laplace equation depends upon intraventricular pressure, wall thickness, and ventricular size and shape. This would be particularly difficult to determine during the ejection phase because of the rapidly changing relation between all these variables. A more practical and simple method of defining the load resisting ejection in the intact heart is to consider the systolic impedance. Though a precise definition of impedance involves consideration of a series of harmonics which describe pressure and flow (Milnor, 1975) , an approximation can be derived from the analysis of the instantaneous relation between pressure and flow during ejection (impedance =P/0, where P and 42 are instantaneous pressure and flow, respectively). Thus, a reduction in ejection impedance can be produced by a reduction in systolic pressure and/or an increase in stroke output. It is clear that ejection impedance is closely related to peripheral vascular resistance. Thus, though the vasodilator drugs which reduce peripheral vascular resistance are often referred to as 'afterload reducing agents', it is preferable to describe their effect in terms of im- For the treatment of pump failure, acute or chronic, several vasodilator agents have been used with beneficial haemodynamic effects. Some of the vasodilator drugs are used intravenously, while some can be administered by other routes. In the following section, the role of vasodilator treatment in the management of pump failure, complicating acute myocardial infarction or chronic refractory heart failure, will be discussed. An attempt will be made to assess the advantages and disadvantages of the various vasodilator agents in relation to the specific objective of treatrment.
Vasodilator treatment for heart failure in acute myocardial infarction
The haemodynamic effects of various vasodilator agents, including sodium nitroprusside (Franciosa et al., 1972; Chatterjee et al., -1973a; Chatterjee and Swan, 1973, 1974) , phentolamine (Kelly et al., 1973; Walinsky et al., 1974; Gould et al., 1974; Perret et al., 1975) , nitroglycerin, both intravenous and sublingual Come et al., 1975; Borer et al., 1975; Armstrong et al., 1975a; Gold et al., 1972; Williams et al., 1975a) , trimetaphan (Shell and Sobel, 1974) , and isosorbide dinitrate (Mantle et al., 1976) , have been investigated in patients with acute myocardial infarction.
The haemodynamic effects of sodium nitro- The haemodynamic effects ofintravenous phentolamine in patients with acute myocardial infarction are similar to those of sodium nitroprusside (Kelly et al., 1973; Walinsky et al., 1974; Gould et al., 1974; Perret et al., 1975) . Phentolamine, an ao-adrenergic blocking agent, also possesses direct smooth muscle relaxing effects. It not only reduces arteriolar tone, but also increases peripheral venous capacitance (Abboud et al., 1968 (Fig. 3). The mechanism responsible for tachycardia with phentolamine is not clear. Increased synthesis and release of cardiac noradrenaline has been shown to occur in experimental animals (Dairman et al., 1968; Bagwell et al., 1970) and might possibly play a role in phentolamine-induced tachycardia. Phentolamine has also been shown to have indirect inotropic effects in experimental animals (Singh et al., 1970; Zahir and Gould, 1971) . From a Stroke volume i ndex NS P C Fig. 3 The haemodynamic effects of phentolamine in patients with acute myocardial infarction are summarisedfrom the published reports (Kelly et al., 1973; Walinsky et al., 1974; Gould et al., 1974; Perret et al., 1975) . Patients were divided into two groups: those with initial left ventricular filling pressure less than 15 mmHg (0) (14 patients), and those with initial left ventricular filling pressure greater than 15 mmHg (0) (37 patients).
Stroke volume increased consistently only in patients with higher left ventricular filling pressure. Heart rate, however, P increased in both groups (Chatterjee and Parmley, 1976: reprinted by permission of Progress in Cardiovascular Diseases). C=control; P= after phentolamine.
120'
.E 80-
group.bmj.com on June 20, 2017 -Published by http://heart.bmj.com/ Downloaded from practical point of view, tachycardia and indirect inotropic effects during.phentolamine therapy are distinct disadvantages, because of the possible increase in myocardial oxygen demand which might jeopardise ischaemic myocardium in these patients.
Nitroglycerin, whether administered intravenously or sublingually, and sublingual isosorbide dinitrate, cause a significant decrease in left ventricular filling pressure and right atrial pressure as a result of their dilating effect on the capacitance venous bed. Arteriolar dilatation with nitrites is less and so the decrease in systemic vascular resistance and left ventricular ejection impedance tend to be less than the reduction in preload. Therefore, though there is almost always a decrease in left ventricular filling pressure, there is little or no increase and may even be a decrease in cardiac output and stroke volume. The changes in stroke volume and in left ventricular filling pressure produced by nitroglycerin in patients with acute myocardial infarction (both sublingual and intravenous) are shown in Fig. 4 ; These haemodynamic data have been collected from published reports (Gold et al., 1972; Williams et al., 1975a; Flaherty et al., 1975; Come et al., 1975; Borer et al., 1975; Armstrong et al., 1975b ibolic response to vasodilator treatment itients with acute myocardial infarction ootential hazard of vasodilator therapy in nts with obstructive coronary artery disease, or without recent myocardial infarction, creased myocardial ischaemia as a result of a ction in arterial pressure and therefore coronary y perfusion pressure. Myocardial perfusion *ver, is dependent not only on the perfusion ure but also on the resistance of the distal iary artery bed and transmyocardial pressure lent (Fortuin et al., 1971) . Furthermore, contant changes in the determinants ofmyocardial en requirement will influence myocardial emia by changing the ratio of oxygen supply emand. Myocardial metabolism during vaso- Fig. 4 Haemodynamic effects of intravenous (45 patients) and sublingual nitroglycerin (28 patients) in acute myocardial infarction. Data collected from published report; Come et al., 1975; Borer et al., 1975; Armstrong et al., 1975a, b; Williams et al., 1975b) . Patients were divided into those with high initial filling pressure (more than 15 mmHg) and those with low initial filling pressure, and the former were further subdivided into those in whom filling pressure fell significantly and those in whom it did not. It is apparent that the predoninant effect of nitroglycerin was to reduce left ventricularfilling pressure, though stroke 30 volune increased slightly in some patients with initially high filling pressure. (Chatterjee et al., 1973a) . This is consistent with the fact that the major determinants of myocardial oxygen demand either remain unchanged or fall: left ventricular systolic and end diastolic pressures decrease, while heart rate and myocardial contractility are unaffected. There was no change in myocardial lactate extraction during vasodilator therapy, indicating that there was no increase in myocardial ischaemia in these patients.
Intravenous phentolamine increases overall myocardial blood flow in patients with acute myocardial infarction, despite a fall in blood pressure (Gould et al., 1975) . However, this increase in coronary blood flow may be partly the result of an increase in myocardial oxygen demand, as a result of tachycardia.
Although the metabolic effects of nitroglycerin have been investigated in patients with chronic ischaemic heart disease Gorlin et al., 1959; Frohlich and Scott, 1962; Luebs et al., 1966; Ganz and Marcus, 1972) (Cohn et al., 1974a; Mueller et al., 1974; Da Luz et al., 1975; Ramanathan et al., 1975) and others deterioration or no change (Kerber and Abboud, 1975; Kerber et al., 1976; Chiariello et al., 1976) . Similarly, there have been contradictory and conflicting reports on the effects of nitroglycerin on the extent of myocardial ischaemic injury, as judged by changes in the magnitude of ST segment elevation after acute myocardial infarction. Decrease in ST segment elevation suggesting reduction of the extent of myocardial ischaemic injury has been observed during nitroglycerin therapy (Borer et al., 1975; Come et al., 1975; Flaherty et al., 1975; Chiariello et al., 1976) . However, no change or even an increase in ST segment elevation has been reported by Lang et al. (1976) . Furthermore, a paradoxical adverse effect of nitroglycerin on segmental left ventricular wall motion has also been reported in patients with obstructive coronary artery disease and 'coronary steal' has been suggested as the underlying mechanism (Codini et al., 1976) . Fam and McGregor (1964) have previously suggested that a 'coronary steal syndrome' might occur with nitroglycerin where there is a large proximal resistance within diseased coronary arteries. This 'coronary steal' from ischaemic myocardium may also occur with nitroprusside or phentolamine and result in increased ischaemia (Chiariello et al., 1976; Brown et al., 1976; Farnham et al., 1976; Engler et al., 1976) .
These limited experimental and clinical investigations suggest that, irrespective of the vasodilator agent used, the effects of vasodilator treatment on the metabolic and mechanical function of ischaemic myocardium are likely to be variable, being determined by concurrent changes in the various factors that influence myocardial perfusion and oxygen demand. Furthermore, extrapolation of the results of experimental studies to the treatment of patients is difficult and should be done with extreme caution. Not only is coronary anatomy different in experimental animals, but the experimental design may be far removed from actual clinical situations. For example, the effects of vasodilators on regional myocardial metabolism and on the extent of myocardial ischaemic injury have been studied in experimental animals within a few minutes of acute coronary artery occlusion, whereas most patients with acute myocardial infarction are 711 group.bmj.com on June 20, 2017 -Published by http://heart.bmj.com/ Downloaded from treated several hours or days after the onset. In addition, most experimental studies have been performed in animals without heart failure, while vasodilator treatment is most useful haemodynamically in patients with significant pump failure. Thus, the effects of vasodilator treatment on relatively ischaemic or hypoxic myocardial segments in patients with obstructive coronary artery disease remain uncertain. But it should be emphasised that in clinical practice a large reduction in arterial pressure, particularly in hypotensive or normotensive patients, whichever vasodilator agent is used, should be avoided since this may aggravate existing myocardial ischaemia. Fortunately, when the objective of treatment is to improve pump function, the beneficial haemodynamic effects of vasodilator treatment can be obtained in many patients without a significant reduction in arterial pressure (Chatterjee et al., 1973a) .
Influence of vasodilator treatment on prognosis of pump failure complicating acute myocardial infarction In recent years, as hospital mortality from primary arrhythmias has strikingly decreased, pump failure has emerged as the primary cause of death in patients with acute myocardial infarction. It has also become apparent that the mortality from pump failure is directly proportional to the severity of depression of cardiac function. Thus, the hospital mortality with conventional therapy is 30 to 40 per cent in patients with frank pulmonary oedema, and approaches 100 per cent when the clinical features of cardiogenic shock are present (Killip and Kimball, 1967; Swan et al., 1970; Wolk et al., 1972; Scheidt et al., 1973; Weber et al., 1973 (Chatterjee et al., 1976c) . Forty-three patients with severe pump failure were treated with nitroprusside (40 patients) or phentolamine (3 patients); clinical data including complications of vasodilator therapy are summarised in Table 2 . Not only clinically, but also on the basis of initial haemodynamic observations As an increase in impedance to left ventricular ejection increases mitral regurgitation (Braunwald et al., 1957) , it is not surprising that vasodilator agents can produce beneficial haemodynamic effects in patients with mitral regurgitation (Chatterjee et al., 1973b; Goodman et al., 1974; Sniderman et al., 1974; Harshaw et al., 1975) . The haemodynamic effects of intravenous sodium nitroprusside infusion are a decrease in systemic and pulmonary vascular resistance, and a decrease in pulmonary artery wedge, right atrial, and pulmonary artery pressures. Left ventricular forward stroke volume and cardiac output increases and usually there is no significant change in heart rate ( Table 5) . Reduction in the regurgitant volume during nitroprusside infusion is indicated by a distinct decrease in the amplitude of the peak v wave in the pulmonary artery wedge pressure (Fig. 6) . Indeed, the calculated regurgitant volume decreases considerably during nitroprusside infusion, with a concomitant increase in forward stroke volume and little change in the total stroke volume (Fig. 7) . This redistribution of the total stroke volume of the left ventricle, with more blood ejected forwards into the aorta and less backwards into the left atrium, accounts for the distinct haemodynamic improvement in these patients. Since the left ventricle operates at a lower filling pressure and end diastolic volume, the calculated ejection fraction usually increases. The decrease in the regurgitant volume, however, may not be entirely the result of the reduction of impedance to left ventricular ejection. Decreased left ventricular chamber size and improved functional integrity of the mitral valve apparatus may play a significant role. Intravenous phentolamine and nitroglycerin (sublingual or topical) produce haemodynamic effects that are very similar to those of nitroprusside. With nitroglycerin, however, forward stroke volume (Pepine et al., 1976; Bolen and Alderman, 1976 (Cohn et al., 1974b; Guiha et al., 1974; Chatterjee, 1975; Miller et al., 1975; Chatterjee et al., 1976a; Chatterjee and Parmley, 1976) . With an adequate dose, cardiac output and stroke volume increase, with decreases in systemic vascular resistance, and in mean arterial and pulmonary artery pressures. Peripheral venous capacitance also increases with a decrease in right atrial and pulmonary artery wedge pressures (Fig. 9 ). This favourable haemodynamic response is usually accompanied by clinical improvement. Intravenous phentolamine produces similar haemodynamic effects (Gould et al., 1969; Majid et al., 1971; Williams et al., 1975b) . These haemodynamic effects of nitroprusside or phentolamine are quickly reversed when intravenous treatment is discontinued. Intravenous treatment is thus clinically applicable only for the short-term management of patients with chronic congestive heart failure or to determine the magnitude of the haemodynamic response before starting nonparenteral vasodilator treatment. Several nonparenteral vasodilators have been investigated for the long-term management of heart failure. Sublingual nitroglycerin (Gold et al., 1972) usually decreases pulmonary and systemic venous pressures. Cardiac output may or may not increase. Clinically, therefore, sublingual nitroglycerin can be used effectively for the treatment of acute pulmonary oedema. The duration of action of sublingual nitroglycerin is extremely short, not exceeding 30 minutes; thus its clinical use in the long-term management of heart failure is limited.
The haemodynamic effects of nitroglycerin ointment, which are similar to those of the sublingual form, last approximately 3 to 5 hours . Though there is usually a significant reduction in systemic and pulmonary venous pressures, the increase in cardiac output is usually only slight. In some patients with severe heart failure there may be no haemodynamic changes (Chatterjee et al., 1976a) , perhaps because of lack of absorption. Furthermore, the effective dose for an individual patient cannot be predicted without haemodynamic measurements.
Sublingual isosorbide dinitrate, in a dose of 2-5 to 15 mg, decreases systemic and pulmonary venous pressure, as a result of an increase in peripheral venous capacitance. Cardiac output increases slightly along with a decrease in arterial pressure (Gray et al., 1975 (Fig. 10) . Frequent administration is therefore necessary. Oral isosorbide dinitrate in a dose of 20 to 40 mg may cause a significant decrease in pulmonary venous pressures for 3 to 4 hours in some patients with chronic congestive heart failure, though its effect on cardiac output is unknown (Franciosa et al., 1974) . Chewable isosorbide dinitrate also appears to be effective in reducing pulmonary and systemic venous pressures (Mikulic et al., 1975) . From the clinical experience reported so far, it appears that most nitrite preparations can produce a significant reduction in pulmonary and systemic venous pressures and so are useful for the relief of pulmonary and systemic venous congestion. As the increase in cardiac output is no more than slight, nitrites may be less effective in those patients with left ventricular failure in whom a low cardiac output is the primary problem. A vasodilator agent with a predominant effect on the precapillary resistance bed may produce a greater increase in cardiac output and therefore be more useful. Preliminary experience with oral hydrallazine, a predominantly arteriolar dilator, in patients with refractory heart failure has shown that it can produce a sustained increase in cardiac output and stroke volume (Chatterjee et al., 1976b; Franciosa and Cohn, 1976) , together with a significant reduction in systemic vascular resistance. When hydrallazine was administered in a dose of 50 to 75 mg every 6 hours, no consistent changes in systemic and pulmonary venous pressures, arterial pressure, or heart rate were observed (Table 6 ). It is not clear why there was no change in heart rate in these patients: a relatively minor reduction in arterial pressure or possibly a sluggish baroreceptor response in patients with chronic heart failure might be responsible. The absence of a significant reduction in arterial pressure in normotensive patients may be an advantage of this drug in the management of patients with heart failure caused by ischaemic heart disease, since coronary artery perfusion pressure would be maintained. On the other hand, systemic and pulmonary venous pressures may remain high and weight gain resulting from an increase in extracellular and plasma volume may occur despite an increase in cardiac output during treatment with oral hydrallazine. The Minutes after isosorbide Fig. 10 Haemodynamic effects of sublingual isosorbide dinitrate in patients with chronic congestive heart failure. These data represent the mean percentage change from control values in 12 patients. There was an increase in cardiac index (CI), stroke volume, and venous capacitance, and a decrease in systemic vascular resistance (TSVR), pulmonary arterial wedge pressure (PAWP), and arterial pressure (Art P), lasting about 90 minutes (Gray et al., 1975: reprinted by permission of American Heart Journal). when the daily dose exceeds 400 mg. Long-term follow-up and further experience will be needed to determine the incidence of these complications in patients with heart failure receiving hydrallazine; without this experience the feasibility of hydrallazine treatment for the long term management of heart failure remains uncertain.
